Immunotherapy and chemotherapy before surgery for advanced throat cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether giving a combination of an immunotherapy drug (PD-1 inhibitor) and chemotherapy before surgery can help treat advanced throat cancer. The goal is to see if this approach shrinks tumors and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have throat cancer (laryngeal or hypopharyngeal) that has not spread to distant parts of the body.
- Your cancer is at a stage where surgery is planned, and you have not had any prior treatment for it.
- You are 18 years or older.
- You are able to tolerate chemotherapy, including cisplatin.
- You are in good general health (able to carry out daily activities with little or no help).
- You have not had an organ or tissue transplant, and you do not have an active autoimmune disease or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of immunotherapy and chemotherapy before surgery can help people whose throat cancer has come back after treatment. The goal is to shrink the tumor before surgery, which may improve outcomes.
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy before surgery can help people with advanced head and neck cancer. It aims to see if the combination is more effective than chemotherapy alone.
This trial tests a new combination of drugs (an immunotherapy called a PD-1 inhibitor, cetuximab, and platinum chemotherapy) given before surgery for advanced throat cancer that requires removing the voice box. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests a combination of two immunotherapy drugs (pembrolizumab and N-803) with or without special immune cells (PD-L1 t-haNK cells) before surgery for head and neck cancer. The goal is to see if this treatment can shrink the cancer or improve the outcome after surgery.
This trial tests a combination of an immunotherapy drug (tirelizumab) with two chemotherapy drugs before surgery for head and neck cancer that has spread to lymph nodes. The goal is to shrink the tumor and improve treatment outcomes.
This trial tests whether adding an immunotherapy drug (PD-1 inhibitor) to standard chemotherapy before surgery improves outcomes for people with advanced laryngeal or hypopharyngeal cancer. The treatment is given before your planned total laryngectomy, and the goal is to shrink the tumor and potentially improve long-term results.
Hear when a new Head and Neck Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.